| Literature DB >> 35409861 |
Giath Gazal1, Khalid H Al-Samadani2, Hamdi Mohammed Alsaidalani1, Ghofran Ali Karbouji1, Abdullah Mohammed Alharbi1.
Abstract
OBJECTIVE: To compare the effectiveness of different oral antibiotics for prevention of dry socket and infection in adults following the surgical extraction of teeth under LA.Entities:
Keywords: dry socket; oral antibiotics; surgical dental extraction
Mesh:
Substances:
Year: 2022 PMID: 35409861 PMCID: PMC8998378 DOI: 10.3390/ijerph19074178
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Description of Study design and study groups.
Comparisons of the total incidence of dry socket signs for the patients in the co-amoxiclav, co-amoxiclav plus metronidazole and co-amoxiclav plus amoxicillin groups 5 days post-operation.
| Treatment Groups | Number of Patients | X2 | ||||
|---|---|---|---|---|---|---|
| Dry socket (DS) signs | Empty socket | Co-amoxiclav 625 mg post-op | Yes | 4 (9%) | 0.672 | 0.715 |
| No | 12 (26%) | |||||
| Co-amoxiclav 625 mg pre-op + Metronidazole 500 mg post-op | Yes | 3 (7%) | ||||
| No | 12 (26%) | |||||
| Amoxiclv 625 mg pre-op + Amoxicillin 500 mg post-op | Yes | 2 (4%) | ||||
| No | 13 (28%) | |||||
| Bone exposure at the site of extraction | Co-amoxiclav 625 mg post-op | Yes | 2 (4%) | 0.399 | 0.819 | |
| No | 14 (31%) | |||||
| Co-amoxiclav 625 mg pre-op + Metronidazole 500 mg post-op | Yes | 3 (7%) | ||||
| No | 12 (26%) | |||||
| Amoxiclv 625 mg pre-op + Amoxicillin 500 mg post-op | yes | 2 (4%) | ||||
| No | 13 (28%) | |||||
| Soft tissue inflammation | Co-amoxiclav 625 mg post-op | Yes | 6 (13%) | 2.349 | 0.309 | |
| No | 10 (22%) | |||||
| Co-amoxiclav 625 mg pre-op + Metronidazole 500 mg post-op | Yes | 2 (4%) | ||||
| No | 13 (28%) | |||||
| Amoxiclv 625 mg pre-op + Amoxicillin 500 mg post-op | Yes | 4 (9%) | ||||
| No | 11 (24%) | |||||
Comparisons between different regimens of oral antibiotics and dry socket symptoms occurrence.
| Treatment Groups | Number of Patients | X2 | ||||
|---|---|---|---|---|---|---|
| Dry socket (DS) symptoms 5 days postoperatively | Throbbing pain | Co-amoxiclav 625 mg post-op | Yes | 8 (18%) | 3.53 | 0.171 |
| No | 8 (18%) | |||||
| Co-amoxiclav 625 mg pre-op + Metronidazole 500 mg post-op | Yes | 3 (7%) | ||||
| No | 12 (26%) | |||||
| Co-amoxiclav 625 mg pre-op + Amoxicillin 500 mg post-op | Yes | 4 (9%) | ||||
| No | 11 (24%) | |||||
| Intraoral halitosis | Co-amoxiclav 625 mg post-op | Yes | 6 (13%) | 5.23 | 0.073 | |
| No | 10 (22%) | |||||
| Co-amoxiclav 625 mg pre-op + Metronidazole 500 mg post-op | Yes | 1 (2%) | ||||
| No | 14 (31%) | |||||
| Co-amoxiclav 625 mg pre-op + Amoxicillin 500 mg post-op | yes | 2 (4%) | ||||
| No | 13 (28%) | |||||
| Bad test | Co-amoxiclav 625 mg post-op | Yes | 8 (18%) | 7.28 | 0.026 | |
| No | 8 (18%) | |||||
| Co-amoxiclav 625 mg pre-op + Metronidazole 500 mg post-op | Yes | 2 (4%) | ||||
| No | 13 (28%) | |||||
| Co-amoxiclav 625 mg pre-op + Amoxicillin 500 mg post-op | Yes | 2 (4%) | ||||
| No | 13 (28%) | |||||
Figure 2Distribution of the dry socket symptoms occurrence for the patients in the co-amoxiclav, co-amoxiclav plus metronidazole and co-amoxiclav plus amoxicillin groups.
Relationship between different regimens of oral antibiotics and SSI occurrence.
| Treatment Groups | Number of Patients | X2 | ||||
|---|---|---|---|---|---|---|
| Surgical site infection (SSI) 5 days postoperatively | Oral swelling | Co-amoxiclav 625 mg post-op | Yes | 2 (4%) | 0.006 | 0.997 |
| No | 14 (32%) | |||||
| Co-amoxiclav 625 mg pre-op + Metronidazole 500 mg post-op | Yes | 2 (4%) | ||||
| No | 13 (28%) | |||||
| Co-amoxiclav 625 mg pre-op + Amoxicillin 500 mg post-op | Yes | 2 (4%) | ||||
| No | 13 (28%) | |||||
| Tenderness to touch | Co-amoxiclav 625 mg post-op | Yes | 5 (11%) | 5.517 | 0.063 | |
| No | 11 (23.5%) | |||||
| Co-amoxiclav 625 mg pre-op + Metronidazole 500 mg post-op | Yes | 0 (0%) | ||||
| No | 15 (33%) | |||||
| Amoxiclv 625 mg pre-op + Amoxicillin 500 mg post-op | yes | 4 (9%) | ||||
| No | 11 (23.5%) | |||||
| Drainage of pus | Co-amoxiclav 625 mg post-op | Yes | 1 (2%) | 1.917 | 0.384 | |
| No | 15 (32.7%) | |||||
| Co-amoxiclav 625 mg pre-op + Metronidazole 500 mg post-op | Yes | 0 (0%) | ||||
| No | 15 (32.7%) | |||||
| Amoxiclv 625 mg pre-op + Amoxicillin 500 mg post-op | Yes | 0 (0%) | ||||
| No | 15 (32.7%) | |||||
| Limitation of mouth opening | Co-amoxiclav 625 mg post-op | Yes | 4(9%) | 2.078 | 0.354 | |
| No | 12(26%) | |||||
| Co-amoxiclav 625 mg pre-op + Metronidazole 500 mg post-op | Yes | 2(4%) | ||||
| No | 13(28%) | |||||
| Amoxiclv 625 mg pre-op + Amoxicillin 500 mg post-op | Yes | 1(2%) | ||||
| No | 14(31%) | |||||
Figure 3Distribution of surgical site infection (SSI) cases among the oral antibiotics groups.